1. X
  2. Journal for ImmunoTherapy of Cancer
Log inSign up
Journal for ImmunoTherapy of Cancer
7,173 posts
Image
user avatar
Journal for ImmunoTherapy of Cancer
@jitcancer
The official journal of @SITCancer, covering all aspects of tumor immunology and cancer immunotherapy. #JITC Editor-in-Chief: Michael T. Lotze, MD
Milwaukee, WI
jitc.bmj.com
Joined July 2019
1,946
Following
9,830
Followers
RepliesRepliesMediaMedia

New to X?

Sign up now to get your own personalized timeline!

Create account

By signing up, you agree to the Terms of Service and Privacy Policy, including Cookie Use.

Terms·Privacy·Cookies·Accessibility·Ads Info·© 2026 X Corp.
Don't miss what's happening
People on X are the first to know.
Log inSign up
  • user avatar
    Journal for ImmunoTherapy of Cancer
    @jitcancer
    Mar 31, 2023
    New #JITC position article and guidelines: Society for Immunotherapy of Cancer (SITC) consensus definitions for immune checkpoint inhibitor-associated immune-related adverse events (irAEs) terminology bit.ly/3zFQgT3 @DrJNaidoo @JulieBrahmer @EladSharonMD @cappelliMD
    Image
    35K035K
  • user avatar
    Journal for ImmunoTherapy of Cancer
    @jitcancer
    Oct 21, 2022
    New #JITC review: Antitumor strategies targeting macrophages: the importance of considering the differences in differentiation/polarization processes between human and mouse macrophages bit.ly/3VLTfmz @lea_paolini
    Image
  • user avatar
    Journal for ImmunoTherapy of Cancer
    @jitcancer
    Feb 1, 2024
    New #JITC commentary: CARs are sharpening their weapons bit.ly/49fMlvJ
    Image
    11K011K
  • user avatar
    Journal for ImmunoTherapy of Cancer
    @jitcancer
    Jan 25, 2022
    New #JITC review: Defining unique clinical hallmarks for immune checkpoint inhibitor-based therapies bit.ly/3tXz49L @peters_solange @lalaniMD
    Image
  • user avatar
    Journal for ImmunoTherapy of Cancer
    @jitcancer
    Nov 15, 2021
    Does tumor burden impact tumor immunity and response to immunotherapy? Important review on this topic @NatRevClinOncol ow.ly/rFWA50GNIpz #JITC SM @MosheOrnsteinMD
    Image
  • user avatar
    Journal for ImmunoTherapy of Cancer
    @jitcancer
    Apr 9, 2022
    Great talk from Yvonne Y. Chen on CAR-T vs CAR-NK at #AACR22. Check out this related #JITC review paper from Australia: Understanding T cell phenotype for the design of effective chimeric antigen receptor T cell therapies bit.ly/3DNeThE
    Image
  • user avatar
    Journal for ImmunoTherapy of Cancer
    @jitcancer
    Aug 3, 2023
    New #JITC review: Chronic immune-related adverse events in patients with cancer receiving immune checkpoint inhibitors: a systematic review bit.ly/47jNdzq
    Image
    11K011K
  • user avatar
    Journal for ImmunoTherapy of Cancer
    @jitcancer
    Dec 22, 2022
    New #JITC short report: Long-term outcomes with nivolumab plus ipilimumab versus sunitinib in first-line treatment of patients with advanced sarcomatoid renal cell carcinoma bit.ly/3PK8p9p @brian_rini @DrChoueiri @montypal
    Image
    16K016K
  • user avatar
    Journal for ImmunoTherapy of Cancer
    @jitcancer
    Jan 20, 2025
    New #JITC review: Advances in the understanding and therapeutic manipulation of cancer immune responsiveness: a Society for Immunotherapy of Cancer (SITC) review bit.ly/40jqaCc @mcquadeMDLAc @MarcoRuella @CSpencerPhD @DrBetofMDPhD @BcellBruno
    Image
    8.8K08.8K
  • user avatar
    Journal for ImmunoTherapy of Cancer
    @jitcancer
    Oct 4, 2022
    New #JITC article: Blockades of effector T cell senescence and exhaustion synergistically enhance antitumor immunity and immunotherapy bit.ly/3e0RKQl
    Image
  • user avatar
    Journal for ImmunoTherapy of Cancer
    @jitcancer
    Jun 8, 2023
    New #JITC review: Vaccinating against cancer: getting to prime time bit.ly/3P0lP2t @gulleyj1 @lawfong
    Image
    30K030K
  • user avatar
    Journal for ImmunoTherapy of Cancer
    @jitcancer
    Aug 22, 2023
    New #JITC article: T-cell receptor beta variable gene polymorphism predicts immune-related adverse events during checkpoint blockade immunotherapy bit.ly/45F6xFp @DrSapnaPatel @ANaingMD
    Image
    32K032K
  • user avatar
    Journal for ImmunoTherapy of Cancer
    @jitcancer
    Dec 21, 2021
    Meet JITC's New Deputy Editor-in-Chief: James L. Gulley, MD, PhD, FACP! Read more in the @sitcancer blog, The Sentinel bit.ly/3GYKAoA @gulleyj1
    Image
  • user avatar
    Journal for ImmunoTherapy of Cancer
    @jitcancer
    May 7, 2022
    Important clinical implications of tumor-reactive CD8+ TIL in patients tumors. #AAI2022 More on TIL manipulation for cancer immunotherapy in @sitcancer #JITC 4-1BB co-stim enhances reinvigoration of CD39+ CD8 T cells from primary & mets in ovarian cancers jitc.bmj.com/content/8/2/e0…
    Image
Advertisement
Advertisement